The study by YolTech is a single-arm, open-label, dose-escalation clinical trial (Clinicaltrials.gov: NCT06082050). This trial's primary objectives are to ...
Friedreich’s ataxia is a genetic, debilitating and life-shortening neuromuscular disease1 Milestone highlights Biogen’s growing portfolio in...
The paper presents final analysis results from a multicenter, double-blind, phase 3, randomized controlled study (NCT05582629) evaluating the efficacy and ...
-Trinity Life Sciences, a leader in global life sciences commercialization solutions, maps out investment strategies and tactics to calibrate a patient-cen...
Seven major research projects to receive more than £14 million to develop new tests, treatments and devices for neurodegenerative diseases includin...
Both of these biomarkers are included in the company’s commercially available Precivity™ blood tests, which help healthcare providers determine...
– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy – – Enfo...
The decision to stop the trial is based on a recommendation from the independent Data Monitoring Committee (DMC) concluding that the results from an interi...
Agilent announced the signing of a Memorandum of Understanding (MOU) with the Sarawak Infectious Disease Centre (SIDC) in East Malaysia. The agreemen...
Thermo Fisher Scientific, the world leader in serving science, today expanded its manufacturing capacity in St. Louis to support biologic therapies for dis...
QIAGEN announced the launch of its QuantiFERON-EBV RUO (Research Use Only) assay. Epstein-Barr virus (EBV), or human herpes virus 4, is estimated in ...
In a powerful display of solidarity with breast cancer warriors and patients, Avantor, a leading global supplier of products, services, and solutions for l...
“This partnership with Cardiac Imaging allows unprecedented access of RUBY Rubidium Elution System™ and RUBY-FILL® (Rubidium Rb82 generator...
The study will evaluate the safety, tolerability, and efficacy of SCI-210, in comparison to CBD monotherapy in treating ASD. Designed as a randomized, doub...
© 2024 Biopharma Boardroom. All Rights Reserved.
